Matrine inhibits TPC‑1 human thyroid cancer cells via the miR‑21/PTEN/Akt pathway

Zhao,Lina; Zhang,Xianyu; Cui,Shusen

doi:10.3892/ol.2018.9006

Matrine inhibits TPC‑1 human thyroid cancer cells via the miR‑21/PTEN/Akt pathway

Authors:
- Lina Zhao
- Xianyu Zhang
- Shusen Cui
View Affiliations

Affiliations: Department of Thyroid Surgery, Jilin University China‑Japan Union Hospital, Changchun, Jilin 130033, P.R. China, Department of Hand Surgery, Jilin University China‑Japan Union Hospital, Changchun, Jilin 130033, P.R. China
Published online on: June 21, 2018 https://doi.org/10.3892/ol.2018.9006
Pages: 2965-2970
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Papillary thyroid cancer (PTC) is the primary type of thyroid cancer and the most widespread endocrine malignancy. Matrine is a traditional Chinese medicine and has been demonstrated as a promising alternative drug for the treatment of TPC‑1 human PTC. In the present study, the therapeutic effects and the underlying molecular mechanisms of matrine on TPC‑1 cells were investigated. Treatment with matrine at the concentrations of 1, 2, 5, 10 and 20 mg/ml inhibited TPC‑1 cell proliferation by up to 95.8% (for 20 mg/ml matrine). Flow cytometry indicated that treatment with 10 mg/ml matrine induced up to 61.8% apoptosis of the TPC‑1 cells and the cell cycle was arrested at the G0/G1 phase following treatment with matrine (2, 5 and 10 mg/ml) for 48 h. Quantitative polymerase chain reaction indicated that the expression of microRNA (miR)‑21 was downregulated and phosphatase and tensin homolog (PTEN) mRNA levels increased up to 1.66‑fold following treatment with matrine, and RAC‑α serine/threonine‑protein kinase (Akt) mRNA levels were downregulated 0.34‑fold following treatment with 5 mg/ml matrine, compared with the normal control group. Western blot analysis indicated that matrine at 2 and 5 mg/ml increased levels of the miR‑21 target PTEN and decreased the levels of phosphorylated (p)Akt. Furthermore, miR‑21 mimic transfection decreased the expression levels of PTEN and increased the levels of pAkt. These results suggested that the miR‑21/PTEN/Akt pathway may be one of the mechanisms by which matrine induces apoptosis and cell cycle arrest in TPC‑1 thyroid cancer cells. Matrine is an alternative potential drug for the treatment of thyroid cancer.

View Figures

View References

1	Giusti F, Falchetti A, Franceschelli F, Marini F, Tanini A and Brandi ML: Thyroid cancer: Current molecular perspectives. J Oncol. 2010:3516792010. View Article : Google Scholar : PubMed/NCBI
2	Braun J and Hüttelmaier S: Pathogenic mechanisms of deregulated microRNA expression in thyroid carcinomas of follicular origin. Thyroid Res. 4 Suppl 1:S12011. View Article : Google Scholar : PubMed/NCBI
3	Leonardi GC, Candido S, Carbone M, Colaianni V, Garozzo SF, Cinà D and Libra M: MicroRNAs and thyroid cancer: Biological and clinical significance (Review). Int J Mol Med. 30:991–999. 2012. View Article : Google Scholar : PubMed/NCBI
4	Benvenga S and Koch CA: Molecular pathways associated with aggressiveness of papillary thyroid cancer. Curr Genom. 15:162–170. 2014. View Article : Google Scholar
5	Wang T, Xu H, Qi M, Yan S and Tian X: miRNA dysregulation and the risk of metastasis and invasion in papillary thyroid cancer: A systematic review and meta-analysis. Oncotarget. 9:5473–5479. 2017.PubMed/NCBI
6	Wang Y, Wei T, Xiong J, Chen P, Wang X, Zhang L, Gao L and Zhu J: Association between genetic polymorphisms in the promoter regions of Let-7 and risk of papillary thyroid carcinoma: A case-control study. Medicine (Baltimore). 94:e18792015. View Article : Google Scholar : PubMed/NCBI
7	Perdas E, Stawski R, Nowak D and Zubrzycka M: The role of miRNA in papillary thyroid cancer in the context of miRNA Let-7 family. Int J Mol Sci. 17:E9092016. View Article : Google Scholar : PubMed/NCBI
8	Lu X, Jia M, Liu Y, Liu Z, Xu H and Geng Z: The role of microRNA-21 in papillary thyroid cancer cells. Chin J Exp Surg. 29:1981–1982. 2012.(In Chinese with English Abstract).
9	Samsonov R, Burdakov V, Shtam T, Radzhabova Z, Vasilyev D, Tsyrlina E, Titov S, Ivanov M, Berstein L, Filatov M, et al: Plasma exosomal miR-21 and miR-181a differentiates follicular from papillary thyroid cancer. Tumour Biol. 37:12011–12021. 2016. View Article : Google Scholar : PubMed/NCBI
10	Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T: Microrna-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
11	Qi L, Bart J, Tan LP, Platteel I, Sluis T, Huitema S, Harms G, Fu L, Hollema H and Berg Av: Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 9:1632009. View Article : Google Scholar : PubMed/NCBI
12	Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo YY: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 18:350–359. 2008. View Article : Google Scholar : PubMed/NCBI
13	Ma X, Kumar M, Choudhury SN, Buscaglia Becker LE, Barker JR, Kanakamedala K, Liu MF and Li Y: Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Proc Natl Acad Sci USA. 108:10144–10149. 2011. View Article : Google Scholar : PubMed/NCBI
14	Liu Y, Xu Y, Ji W, Li X, Sun B, Gao Q and Su C: Anti-tumor activities of matrine and oxymatrine: Literature review. Tumour Biol. 35:5111–5119. 2014. View Article : Google Scholar : PubMed/NCBI
15	An Q, Han C, Zhou Y, Li F, Li D, Zhang X, Yu Z, Duan Z and Kan Q: Matrine induces cell cycle arrest and apoptosis with recovery of the expression of miR-126 in the A549 non-small cell lung cancer cell line. Mol Med Rep. 14:4042–4048. 2016. View Article : Google Scholar : PubMed/NCBI
16	Wu L, Wang G, Wei J, Huang N, Zhang S, Yang F, Li M, Zhou G and Wang L: Matrine derivative YF-18 inhibits lung cancer cell proliferation and migration through down-regulating Skp2. Oncotarget. 8:11729–11738. 2017.PubMed/NCBI
17	Lu Z, Xiao Y, Liu X, Zhang Z, Xiao F and Bi Y: Matrine reduces the proliferation of A549 cells via the p53/p21/PCNA/eIF4E signaling pathway. Mol Med Rep. 15:2415–2422. 2017. View Article : Google Scholar : PubMed/NCBI
18	Luo C, Zhu Y, Jiang T, Lu X, Zhang W, Jing Q, Li J, Pang L, Chen K, Qiu F, et al: Matrine induced gastric cancer MKN45 cells apoptosis via increasing pro-apoptotic molecules of Bcl-2 family. Toxicology. 229:245–252. 2007. View Article : Google Scholar : PubMed/NCBI
19	Li H, Xie S, Liu X, Wu H, Lin X, Gu J, Wang H and Duan Y: Matrine alters microRNA expression profiles in SGC-7901 human gastric cancer cells. Oncol Rep. 32:2118–2126. 2014. View Article : Google Scholar : PubMed/NCBI
20	He M, Jiang L, Li B, Wang G, Wang J and Fu Y: Oxymatrine suppresses the growth and invasion of MG63 cells by up-regulating PTEN and promoting its nuclear translocation. Oncotarget. 8:65100–65110. 2017.PubMed/NCBI
21	Peng X, Zhou D, Wang X, Hu Z, Yan Y and Huang J: Matrine suppresses proliferation and invasion of SGC7901 cells through inactivation of PI3K/Akt/uPA pathway. Ann Clin Lab Sci. 46:457–462. 2016.PubMed/NCBI
22	Niu H, Zhang Y, Wu B, Zhang Y, Jiang H and He P: Matrine induces the apoptosis of lung cancer cells through downregulation of inhibitor of apoptosis proteins and the Akt signaling pathway. Oncol Rep. 32:1087–1093. 2014. View Article : Google Scholar : PubMed/NCBI
23	Li LQ, Li XL, Wang L, Du WJ, Guo R, Liang HH, Liu X, Liang DS, Lu YJ, Shan HL and Jiang HC: Matrine inhibits breast cancer growth via miR-21/PTEN/Akt pathway in MCF-7 cells. Cell Physiol Biochem. 30:631–641. 2012. View Article : Google Scholar : PubMed/NCBI
24	Oldham ED, Nunes LM, Varela-Ramirez A, Rankin SE, Knutson BL, Aguilera RJ and Lehmler HJ: Cytotoxic activity of triazole-containing alkyl β-D-glucopyranosides on a human T-cell leukemia cell line. Chem Cent J. 9:32015. View Article : Google Scholar : PubMed/NCBI
25	Robles-Escajeda E, Lerma D, Nyakeriga AM, Ross JA, Kirken RA, Aguilera RJ and Varela-Ramirez A: Searching in mother nature for anti-cancer activity: Anti-proliferative and pro-apoptotic effect elicited by green barley on leukemia/lymphoma cells. PLoS One. 8:e735082013. View Article : Google Scholar : PubMed/NCBI
26	Jin H, Sun Y, Wang S and Cheng X: Matrine activates PTEN to induce growth inhibition and apoptosis in V600EBRAF harboring melanoma cells. Int J Mol Sci. 14:16040–16057. 2013. View Article : Google Scholar : PubMed/NCBI
27	Fragni M, Bonini SA, Bettinsoli P, Bodei S, Generali D, Bottini A, Spano PF, Memo M and Sigala S: The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines. Naunyn Schmiedebergs Arch Pharmacol. 389:529–538. 2016. View Article : Google Scholar : PubMed/NCBI
28	Lv C, Hao Y and Tu G: MicroRNA-21 promotes proliferation, invasion and suppresses apoptosis in human osteosarcoma line MG63 through PTEN/Akt pathway. Tumour Biol. 37:9333–9342. 2016. View Article : Google Scholar : PubMed/NCBI
29	Yu P, Liu Q, Liu K, Yagasaki K, Wu E and Zhang G: Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-kappaB signaling. Cytotechnology. 59:219–229. 2009. View Article : Google Scholar : PubMed/NCBI
30	Liang CZ, Zhang JK, Shi Z, Liu B, Shen CQ and Tao HM: Matrine induces caspase-dependent apoptosis in human osteosarcoma cells in vitro and in vivo through the upregulation of Bax and Fas/FasL and downregulation of Bcl-2. Cancer Chemother Pharmacol. 69:317–331. 2012. View Article : Google Scholar : PubMed/NCBI
31	Yan LX, Wu QN, Zhang Y, Li YY, Liao DZ, Hou JH, Fu J, Zeng MS, Yun JP, Wu QL, et al: Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res. 13:R22011. View Article : Google Scholar : PubMed/NCBI